MedJ takes you straight to ASCO 2025.
Professor Yelena Y. Janjigian from Memorial Sloan Kettering Cancer Center presented groundbreaking Phase III data on the world's first perioperative immunotherapy regimen—durvalumab combined with FLOT chemotherapy for resectable gastric cancer/gastroesophageal junction adenocarcinoma (GC/GEJC)—and decoded the new treatment strategy in depth.